Showing results (391-400 of 406) with videos related to

Sort By:
Pageof 41
Annals of Hematology|September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAlice Fabarius, Lida Kalmanti, Christian T Dietz, et al.
Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology|November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood Cancer Discovery|June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple MyelomaFaith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Pageof 41